<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Echinococcosis: Treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Echinococcosis: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Echinococcosis: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pedro L Moro, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">D Nageshwar Reddy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Echinococcosis is caused by infection with the tapeworm <em>Echinococcus</em>, which belongs to the family Taeniidae. Four species of <em>Echinococcus </em>cause infection in humans. <em>E. granulosus </em>and <em>E. multilocularis </em>are the most common, causing cystic echinococcosis and alveolar echinococcosis, respectively. </p><p>The two other species, <em>E. vogeli </em>and <em>E. oligarthus</em>, cause polycystic echinococcosis but have rarely been associated with human infection. Two new species have been identified: <em>E. shiquicus</em> in small mammals from the Tibetan plateau and <em>E. felidis</em> in African lions; their transmission potential to humans is not known [<a href="#rid1">1</a>].</p><p>The treatment of cystic and alveolar echinococcal infection will be reviewed here. The clinical manifestations, diagnosis, epidemiology, and control of echinococcal infection are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5669.html" rel="external">"Echinococcosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5668.html" rel="external">"Epidemiology and control of echinococcosis"</a>.)</p><p>This section was prepared or accomplished by Pedro Moro in his personal capacity. The opinions expressed in this article are the author's own and do not reflect the view of the United States Centers for Disease Control and Prevention, the Department of Health and Human Services, or the United States government. </p><p class="headingAnchor" id="H2"><span class="h1">CYSTIC ECHINOCOCCOSIS (E. GRANULOSUS)</span></p><p class="headingAnchor" id="H5041303"><span class="h2">Management approach</span><span class="headingEndMark"> — </span>Treatment of echinococcosis usually involves antiparasitic therapy combined with either surgical resection of the cyst or percutaneous aspiration and instillation of scolicidal agents [<a href="#rid1">1-3</a>]. </p><p class="headingAnchor" id="H1450125860"><span class="h3">Antiparasitic therapy</span><span class="headingEndMark"> — </span>Antiparasitic therapy may be used for definitive management in selected cases; it is also a useful adjunctive therapy to surgery and percutaneous treatment. <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> is the primary antiparasitic agent for treatment of <em>E. granulosus</em> [<a href="#rid4">4</a>]. Albendazole is poorly absorbed and should be ingested with food, ideally with a fatty meal to increase bioavailability (15 mg/kg/day, divided into two doses, to maximum 400 mg orally twice daily with food). In the absence of albendazole, or for patients with severe adverse reactions to albendazole, <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a> may be used as an alternative therapy; it is less well absorbed than albendazole [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2992976383"><span class="h4">Definitive treatment</span><span class="headingEndMark"> — </span>Initial management with drug treatment alone is appropriate for management of small World Health Organization (WHO) stage CE1 and CE3a cysts (eg, cysts with a single compartment and diameter &lt;5 cm). Treatment should be administered without interruption [<a href="#rid1">1</a>]. The optimal duration is uncertain; one to three months may be appropriate, depending on clinical factors; up to six months may be required.</p><p>Drug treatment alone is usually not effective for treatment of cysts with diameter &gt;5 cm or for treatment of WHO stage CE2 or CE3b cysts (which have multiple compartments) [<a href="#rid5">5</a>]. Other circumstances in which drug treatment alone may be warranted include management of multiple liver cysts &lt;5 cm, management of cysts deep in liver parenchyma that are not amenable to percutaneous treatment, and/or peritoneal cysts [<a href="#rid4">4</a>]. WHO stage CE4 and CE5 cysts are inactive; antiparasitic treatment is not warranted in such cases.</p><p class="headingAnchor" id="H665516694"><span class="h4">Adjunctive treatment</span><span class="headingEndMark"> — </span>Drug treatment is a useful adjunctive therapy to surgery and percutaneous treatment. Perioperative drug therapy with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (or <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a>) reduces the risk of recurrent disease by inactivating protoscolices [<a href="#rid6">6-8</a>]. It also softens the cyst, facilitating removal. The optimal duration of treatment is uncertain; in general treatment should be initiated at least four days prior to surgery (the WHO suggests 4 to 30 days preoperatively) and should be continued for at least one month (albendazole) or three months (mebendazole) following surgery [<a href="#rid9">9-11</a>].</p><p>Drug treatment may be appropriate for patients who cannot undergo definitive cyst removal via percutaneous treatment or surgery, although drug treatment alone is generally not sufficient for definitive management in such cases. Drug treatment is also appropriate following spontaneous cyst rupture to reduce the risk of secondary echinococcosis from seeding of protoscolices in the abdominal cavity for one month (<a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a>) or three months (<a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a>) [<a href="#rid9">9-11</a>].</p><p class="headingAnchor" id="H2436473917"><span class="h4">Drug selection</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> is the primary antiparasitic agent for treatment of <em>E. granulosus</em>; availability and/or cost may be prohibitive in some regions. <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">Mebendazole</a> and <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> are less effective agents; in the absence of albendazole, or for patients with severe adverse reactions to albendazole, mebendazole may be used as an alternative therapy [<a href="#rid4">4</a>].</p><p><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> inhibits microtubules assembly, leading to impaired glucose absorption and causing glycogen depletion followed by degeneration of the endoplasmic reticulum and mitochondria of the germinal layer, leading to cell death [<a href="#rid12">12</a>]. The outcome of treatment with albendazole depends on host characteristics, cyst size, age, and location [<a href="#rid13">13</a>]. Cumulative experience with albendazole suggests that treatment leads to cyst resolution in up to 30 percent of patients, size reduction in another 30 to 50 percent, and no change in 20 to 40 percent [<a href="#rid14">14-16</a>]. A lower likelihood of response has been observed in the setting of older patient age and longer duration of infection [<a href="#rid17">17</a>].</p><p><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> has a more favorable pharmacokinetic profile than <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a> and may be given for a shorter duration of therapy [<a href="#rid5">5,14,17-27</a>]. Albendazole is usually dosed 10 to 15 mg/kg per day in two divided doses; the usual dose for adults is 400 mg twice daily. Absorption is improved by taking albendazole with a fatty meal. Mebendazole is dosed 40 to 50 mg/kg per day in three divided doses.</p><p><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> is generally well tolerated. Adverse effects include reversible hepatotoxicity (1 to 5 percent), cytopenia (&lt;1 percent), and alopecia (&lt;1 percent). Increased levels of aminotransferases may occur as a result of drug toxicity or parasite killing. Rarely, agranulocytosis has been reported. Dizziness, headache, vomiting, and rash have also been described. These drugs should not be used in patients with significant underlying liver disease or bone marrow suppression. Laboratory monitoring including blood count and liver function tests should be checked at two-week intervals for the first three months, then monthly.</p><p>An increase in aminotransferases that is more than fivefold above the upper limit of normal should prompt discontinuation of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> and consideration of alternative treatment approaches such as percutaneous or surgical management. If an alternative therapeutic agent is required, <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> may be a reasonable alternative to albendazole.</p><p><a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> should be avoided during pregnancy because of potential teratogenicity; if feasible, treatment should be delayed until after delivery [<a href="#rid1">1</a>]. Data on use of albendazole in children &lt;6 years are limited.</p><p><a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">Praziquantel</a> has been shown to have protoscolicidal activity, although the efficacy of praziquantel in clinical studies is variable, and, thus far, it does not have a definitive role for primary drug therapy [<a href="#rid28">28-31</a>]. Praziquantel has been used alone and in combination with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> [<a href="#rid13">13,28,29,32-35</a>]. Limited case series suggest the combination of albendazole and praziquantel may be superior to albendazole alone; further study is needed [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2694646987"><span class="h3">Cyst management</span></p><p class="headingAnchor" id="H4049772267"><span class="h4">Overview of approach</span><span class="headingEndMark"> — </span>Surgery has been the traditional approach for treatment of CE; subsequently, alternative approaches have been introduced and have replaced surgery as the treatment of choice in some cases [<a href="#rid37">37,38</a>].</p><p>In general, the clinical approach depends on the World Health Organization (WHO) diagnostic classification (<a class="graphic graphic_table graphicRef71806" href="/z/d/graphic/71806.html" rel="external">table 1</a> and <a class="graphic graphic_diagnosticimage graphicRef87459" href="/z/d/graphic/87459.html" rel="external">image 1</a>). Stage CE1 and CE3a cysts have a single compartment; such cysts that are &lt;5 cm may be treated with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> alone [<a href="#rid1">1</a>]. In settings where albendazole treatment with follow-up monitoring is not feasible, definitive management with percutaneous treatment via puncture, aspiration, injection, and reaspiration (PAIR) is an acceptable alternative approach. Stage CE1 and CE3a cysts that are &gt;5 cm may be treated with albendazole in combination with PAIR. In situations where albendazole treatment is not feasible, percutaneous treatment with PAIR (in the absence of adjunctive drug therapy) is an acceptable alternative approach [<a href="#rid1">1</a>]. Issues related to drug therapy are discussed below. (See <a class="local">'Antiparasitic therapy'</a> above.)</p><p>Stage CE2 and CE3b cysts have many compartments that require individual puncture; patients with such cysts commonly relapse after PAIR [<a href="#rid39">39</a>]. Therefore, management of these cysts requires either modified catheterization technique (eg, non-PAIR percutaneous therapy) or surgery (with adjunctive drug therapy) [<a href="#rid1">1</a>]. The optimal choice between these approaches is uncertain and further study is needed.</p><p>Stages CE4 and CE5 are inactive cysts that may be managed with observation [<a href="#rid39">39-41</a>]. </p><p>There are few randomized trials comparing different treatments, and the level of evidence supporting the use of one therapeutic modality over another is low. In one study of 32 patients with hepatic cysts comparing percutaneous drainage alone, <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> alone, and percutaneous drainage in combination with albendazole, those who received combination therapy had the greatest size reduction observed ultrasonographically [<a href="#rid42">42</a>]. Subsequently, a randomized trial performed among 50 patients demonstrated that outcomes among those who underwent percutaneous drainage (in combination with albendazole) were comparable to outcomes among patients who underwent surgery (with no albendazole therapy) [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H3"><span class="h4">Surgery</span></p><p class="headingAnchor" id="H2911797969"><span class="h5">Indications</span><span class="headingEndMark"> — </span>Surgery is the treatment of choice for management of complicated cysts (eg, rupture cyst, cysts with biliary fistulae, cysts compressing vital structures, cysts with secondary infection or hemorrhage) [<a href="#rid1">1</a>]. Surgery is also warranted for management of cysts with many daughter vesicles that are not suitable for percutaneous treatment (eg, WHO stage CE2 and CE3b) (<a class="graphic graphic_table graphicRef71806" href="/z/d/graphic/71806.html" rel="external">table 1</a> and <a class="graphic graphic_diagnosticimage graphicRef87459" href="/z/d/graphic/87459.html" rel="external">image 1</a>) [<a href="#rid1">1,44</a>]. Other indications for surgery include cyst diameter &gt;10 cm, superficial cyst at risk of rupture due to trauma, and extrahepatic disease (lung [<a href="#rid45">45,46</a>], bone [<a href="#rid17">17,47</a>], brain [<a href="#rid17">17,48,49</a>], kidney, or other site) [<a href="#rid4">4,37,40,50,51</a>]. Surgery is also appropriate in settings where percutaneous treatment is not available.</p><p>Adjunctive drug therapy should be administered to minimize risk of secondary echinococcosis from seeding of protoscolices in the abdominal cavity in the event of fluid spillage. <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> is generally administered beginning one week prior to surgery and continued for at least four weeks postoperatively. Some use <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> in addition to albendazole, although there is no clear evidence regarding its efficacy [<a href="#rid29">29,52</a>]. (See <a class="local">'Adjunctive treatment'</a> above.)</p><p>Surgery may cure the patient, but morbidity, mortality, and relapse rates can vary widely [<a href="#rid49">49</a>]. Complications include secondary infection of cyst cavity, intraabdominal abscess, biliary fistula, sclerosing cholangitis, and spillage of cyst contents leading to secondary echinococcosis and/or anaphylaxis. Postoperative complications occur in less than 1 percent of cases; recurrent echinococcosis occurs in 2 to 25 percent of cases [<a href="#rid40">40,53</a>]. These rates depend on the location and size of the cyst and the surgeon's experience.</p><p class="headingAnchor" id="H5"><span class="h5">Techniques</span><span class="headingEndMark"> — </span>The goals of surgical therapy consist of evacuating the cyst and obliterating the residual cavity [<a href="#rid51">51</a>]. Every effort should be made to avoid fluid spillage, which can lead to secondary seeding of infection and/or anaphylaxis. The safest and most effective surgical procedure is uncertain; the relative advantages of the different approaches have not been clearly established. Traditional approaches have included radical resection including pericystectomy or more conservative techniques. Laparoscopic surgery may be an alternative to open surgery in some cases.</p><p>The surgical approach must be individualized depending on the cyst features [<a href="#rid54">54</a>]. Removal of the intact cyst is preferred, if feasible [<a href="#rid55">55-58</a>]. Alternatively, the cyst can be opened and sterilized with protoscolicidal agents, followed by evacuation of cyst contents and removal of the pericystic tissue. In one study including 132 patients with liver cysts treated with a variety of surgical procedures, cyst excision and omentoplasty were associated with the most favorable clinical results and lowest complication rates; a recurrence rate of 4.5 percent was observed with 4.5 years median follow-up [<a href="#rid59">59</a>].</p><p>Every effort should be made to avoid fluid spillage, which can lead to secondary seeding of infection and/or anaphylaxis. For circumstances in which intact removal of the cyst is not feasible, a protoscolicidal agent such as 20% hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> should be injected into the cyst prior to removing the contents. In addition, the surgical field should be protected with pads soaked in protoscolicidal agents. However, protoscolicidal agents should not be used in the setting of biliary communication, to minimize the risk of sclerosing cholangitis or pancreatitis. The anatomy of biliary communication should be defined intraoperatively (radio-opaque dye may be useful if available); any biliary leaks should be repaired surgically prior to application of the protoscolicidal agent.</p><p>The most commonly used protoscolicidal agent is 20% hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>; the solution should be in contact with the germinal layer for at least 15 minutes (<a class="graphic graphic_figure graphicRef87460" href="/z/d/graphic/87460.html" rel="external">figure 1</a>). <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a>, <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>, and <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> solutions have been used as protoscolicidal agents, although their efficacy and safety require further study [<a href="#rid60">60,61</a>]. Formalin has been associated with sclerosing cholangitis and should not be used.</p><p>If spillage does occur, the peritoneum should be washed with hypertonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>. The patient should be treated with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (three to six months) and a brief course of <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a> (seven days) should also be administered [<a href="#rid33">33</a>]. The management of anaphylaxis is described separately. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p>Laparoscopic surgery has been described for treatment of <em>Echinococcus</em>, although no randomized trials comparing laparoscopy with open procedures have been performed [<a href="#rid37">37</a>]. Laparoscopy may be associated with increased risk of spillage due to elevated intraabdominal pressures caused by pneumoperitoneum [<a href="#rid37">37</a>]. Laparoscopy is most likely to be successful in the setting of anteriorly located hepatic cysts [<a href="#rid62">62</a>]. Exclusion criteria for laparoscopy include deep intraparenchymal cysts, posterior cysts situated close to the vena cava, and presence of more than three cysts with calcified walls [<a href="#rid37">37,63-66</a>].</p><p>Surgical approaches for management of lung cysts include lobectomy, wedge resection, pericystectomy, intact endocystectomy, and capitonnage. In a study of 842 patients followed for 3 to 20 years, a recurrence rate of 1.9 percent was noted after intact endocystectomy [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H4200952222"><span class="h5">Complications</span><span class="headingEndMark"> — </span>Postoperative complications may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive jaundice (often attributable to echinococcal remnants in the biliary tree) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of an external biliary fistula occurs in up to 2 percent of patients, typically two to four weeks postoperatively)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sphincter of Oddi stenosis, bile duct stricture, or sclerosing cholangitis − These are late complications most commonly observed in patients who underwent cyst sterilization with formalin </p><p></p><p>Management of these complications is discussed below. (See <a class="local">'Patients with biliary complications'</a> below.)</p><p class="headingAnchor" id="H2662872837"><span class="h4">Percutaneous management</span><span class="headingEndMark"> — </span>There are two categories of percutaneous techniques. The first approach aims to destroy the germinal layer with scolicidal agents (<a class="graphic graphic_figure graphicRef87460" href="/z/d/graphic/87460.html" rel="external">figure 1</a>). This is done via the PAIR technique [<a href="#rid68">68</a>]. PAIR is usually effective for definitive treatment of cysts that do not have daughter cysts (eg, WHO stage CE1 and CE3a).</p><p>The second approach consists of evacuating the entire cyst with a large-bore catheter. This is generally done for management of cysts that are difficult to drain or tend to relapse after PAIR, such as WHO stage CE2 and CE3b cysts (which may contain daughter cysts). Establishing whether daughter cysts are present is important for guiding treatment, since the presence of daughter cysts reduces the likelihood of successful definitive treatment with PAIR.</p><p>Percutaneous treatment is associated with risk for anaphylaxis; in one review of treatment for nearly 6000 cysts, anaphylaxis occurred in 1.6 percent of patients [<a href="#rid69">69</a>]. <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> should be administered for at least one month following percutaneous treatment [<a href="#rid44">44</a>]. (See <a class="local">'Adjunctive treatment'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h5">PAIR procedure</span><span class="headingEndMark"> — </span>PAIR is less invasive than surgery and can be both a diagnostic and therapeutic procedure [<a href="#rid70">70</a>]. The cure rate with PAIR for appropriately selected cysts is &gt;95 percent [<a href="#rid71">71-73</a>]. Among 231 liver cysts in 163 Italian patients treated with PAIR (ethanol was the scolicidal agent), one relapse was observed after four years of follow-up; this was successfully treated with repeat PAIR [<a href="#rid72">72</a>]. Establishing whether daughter cysts are present is important for guiding treatment, since the presence of daughter cysts generally precludes use of PAIR for definitive management.</p><p>PAIR may be used for primary treatment of WHO stage CE1 and CE3a cysts (eg, cysts that do not have daughter cysts), for treatment following relapse of CE1 or CE3a cysts managed previously with medical therapy alone, or for treatment following relapse after surgery (in the absence of daughter cysts). PAIR has been used successfully for management of cysts in the liver and other abdominal sites (eg, abdominal cavity, spleen, kidney), although many experts would approach these lesions surgically. Cysts in extra-abdominal sites such as lung or bone are less amenable to management with PAIR.</p><p>PAIR is performed under ultrasound or computed tomography (CT) guidance. Following cyst puncture, aspirated fluid should be evaluated histopathologically for presence of protoscolices. Following injection of the protoscolicidal agent, reaspiration should be performed after at least 10 to 15 minutes. The presence of protoscolices in the reaspirated fluid should prompt repeat protoscolicidal injection. Follow-up after PAIR is discussed below. (See <a class="local">'Follow-up'</a> below.)</p><p>Adjunctive drug therapy with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> or <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a> should be administered at least four hours prior to PAIR. Albendazole should be continued for one month after the procedure; mebendazole should be continued for three months after the procedure [<a href="#rid1">1,4,53</a>]. Issues related to drug therapy are discussed below. (See <a class="local">'Antiparasitic therapy'</a> above.)</p><p>Further study is needed regarding the optimal approach, including use of needle versus catheter, quantity of protoscolicidal agent, and duration of follow-up required.</p><p>PAIR should not be performed in the following circumstances [<a href="#rid40">40</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cyst with nondrainable solid material or echogenic foci</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial cyst at risk of rupture into the abdominal cavity</p><p class="bulletIndent1"><span class="glyph">●</span>Cyst that has ruptured into the peritoneum</p><p class="bulletIndent1"><span class="glyph">●</span>Cyst with biliary communication</p><p class="bulletIndent1"><span class="glyph">●</span>Inactive or calcified cyst</p><p></p><p>Risks of PAIR include spillage of cyst contents into the peritoneum (which can lead to secondary echinococcosis, urticaria, and/or anaphylaxis), chemical sclerosing cholangitis, biliary fistula (6 percent), local recurrence (3 percent), and bleeding and infection (4 percent) [<a href="#rid73">73-76</a>]. Fever and urticaria occur in 11 to 13 percent of cases [<a href="#rid73">73,74</a>]; the risk of anaphylaxis is 0.5 percent and has been reduced with development of fine needles and catheters and advances in imaging techniques [<a href="#rid74">74</a>].</p><p>Endoscopy can be useful both before and after PAIR to evaluate for cyst communication with the biliary tree [<a href="#rid72">72,77</a>]. (See <a class="local">'Patients with biliary complications'</a> below.)</p><p class="headingAnchor" id="H2662872905"><span class="h5">Modified catheterization techniques</span><span class="headingEndMark"> — </span>Modified catheterization techniques are used to remove the entire endocyst and daughter cysts from the cyst cavity using large-bore catheters and cutting devices together with an aspiration apparatus [<a href="#rid1">1</a>]. This approach (in combination with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> if available) may be appropriate for cysts that are difficult to drain via PAIR and for management of WHO stage CE2 and CE3b cysts, which have many compartments so commonly relapse after PAIR [<a href="#rid39">39,78</a>]. The alternative management for such cysts is surgery. The optimal choice between these approaches is uncertain. Experience with modified catheterization techniques and data regarding outcomes are limited; further study is needed.</p><p class="headingAnchor" id="H1921067385"><span class="h2">Patients with biliary complications</span><span class="headingEndMark"> — </span>Patients with biliary complications of echinococcosis may warrant endoscopic retrograde cholangiopancreatography (ERCP) [<a href="#rid79">79-81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive jaundice or cholangitis − Patients with obstructive jaundice or cholangitis (either prior to or following surgery) may warrant sphincterotomy, followed by removal of cysts and membranes with the help of a basket or an occlusion balloon [<a href="#rid82">82</a>]. In addition, hydatid sand and small daughter cysts may be flushed from the bile duct via <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> irrigation. In the setting of cholangitis, a nasobiliary drain may be placed, followed by extraction of hydatid cysts and membranes (with or without sphincterotomy) [<a href="#rid83">83</a>]. The drained bile can be examined for hydatid hooklets or membranes. (See  <a class="medical medical_review" href="/z/d/html/5669.html" rel="external">"Echinococcosis: Clinical manifestations and diagnosis", section on 'Cyst aspiration or biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>External biliary fistula − Management consists of external biliary fistula consists of endoscopic biliary stenting for approximately four to six weeks [<a href="#rid84">84</a>]; sphincterotomy may also be effective [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sphincter of Oddi stenosis − Management of sphincter of Oddi stenosis consists of sphincterotomy [<a href="#rid86">86</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bile duct stricture – For most patients with a biliary stricture associated with cholestasis, management consists of ERCP with balloon dilation and placement of a temporary biliary stent [<a href="#rid87">87-89</a>]. Several endoscopic sessions may be required to achieve stricture resolution. Management of other benign biliary strictures is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/637.html" rel="external">"Endoscopic management of postcholecystectomy biliary complications", section on 'Biliary stricture'</a>.)</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Cystic echinococcosis can relapse years after treatment. Evaluating the success of therapy can is difficult since the natural history of infection can be highly variable. Cysts may continue growing (1 to 50 mm per year), persist with no change, rupture spontaneously, or resolve completely.</p><p>The optimal approach to monitoring is uncertain and must be individualized according to patient characteristics and available resources [<a href="#rid90">90</a>]. Follow-up usually consists of ultrasound or other imaging (CT or magnetic resonance imaging [MRI]) at three- to six-month intervals until the findings are stable, followed by yearly monitoring. Follow-up for up to five years is usually warranted to evaluate for recurrence; in some cases, three years may be sufficient if radiographic findings are stable at 12, 24, and 36 months [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H13253170"><span class="h3">Ultrasonography</span><span class="headingEndMark"> — </span>Ultrasonography may be useful in assessing the response to therapy but has limitations. Ultrasound findings that appear to correlate with effective therapy include [<a href="#rid42">42,91</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete cyst disappearance</p><p class="bulletIndent1"><span class="glyph">●</span>Reduction in cyst size and volume</p><p class="bulletIndent1"><span class="glyph">●</span>Increase in proportion of solid component of cyst</p><p class="bulletIndent1"><span class="glyph">●</span>Thickening and irregularity of the cyst wall</p><p class="bulletIndent1"><span class="glyph">●</span>Within multivesicular cysts, reduction in size and/or number of daughter cysts</p><p></p><p>Ultrasound findings that appear to correlate with relapse include development of new cysts, increase in cyst size or volume, and increase in liquid component of the cyst [<a href="#rid1">1,92</a>].</p><p>Ultrasound lacks sensitivity for determination of cyst viability; in one study including 55 patients, no ultrasonographic changes were observed among 41 percent of nonviable cysts surgically removed following <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> therapy [<a href="#rid9">9</a>].</p><p>On CT or MRI, degenerating cysts are often surrounded by a dense halo.</p><p class="headingAnchor" id="H26"><span class="h3">Serology</span><span class="headingEndMark"> — </span>The optimal serologic test for monitoring patients on treatment for hydatid disease is uncertain. Frequently, serologic titers fall one to two years following successful surgery and rise again in the setting of recurrence. However, antibodies may remain elevated even many years after successful cyst removal [<a href="#rid13">13,93</a>].</p><p>There are some antigens that appear promising for use of serology in monitoring following treatment [<a href="#rid94">94,95</a>]. One study evaluated six serologic tests for postoperative monitoring of pulmonary hydatid disease in 79 surgically confirmed cases [<a href="#rid96">96</a>]. Latex agglutination, passive hemagglutination, immunoelectrophoresis, and specific immunoglobulin (Ig)E, IgM, and IgG enzyme-linked immunosorbent assay (ELISA) tests were used. All tests showed an increase in titer in the majority of patients within the first three months after surgery, likely as a result of antigen release during cyst manipulation. Specific IgG ELISA was the most sensitive measure of response to treatment (84 percent); specific IgE ELISA was the least sensitive (44 percent). All serologic tests showed decreasing antibody titers from three months after surgery in patients without relapse; immunoelectrophoresis, specific IgE ELISA, and specific IgM ELISA tests became negative at two years. Specific IgG ELISA was the slowest to become negative and was still positive five years after surgery in 17 percent of cases. Patients who relapsed showed either persistently high (early relapse) or initial decrease and subsequent increase (late relapse) in antibody titers in all serologic tests.</p><p>Other studies have suggested that less sensitive tests such as immunoelectrophoresis and IgM/IgE ELISA become negative earlier after successful treatment than more sensitive tests such as hemagglutination, latex agglutination, or specific IgG ELISA. The more sensitive tests may be positive in &gt;40 percent of patients 4 to 5 years after surgery and can remain positive for more than 10 years.</p><p class="headingAnchor" id="H4172118646"><span class="h2">Outcome</span><span class="headingEndMark"> — </span>The outcome of infection varies with the stage of the disease. One study reported on the long-term outcome of 33 patients with asymptomatic liver hydatid cysts [<a href="#rid97">97</a>]. The natural history of infection was variable. Approximately 15 percent of patients had undergone surgery 10 to 12 years after the initial diagnosis. Among patients who did not undergo surgery, 75 percent remained asymptomatic; 57 percent did not have a change in the size of the cyst by imaging.</p><p>Calcification usually requires 5 to 10 years to develop and occurs most commonly with hepatic cysts but rarely with pulmonary or bone cysts. Total calcification of the cyst wall suggests that the cyst may be nonviable.</p><p class="headingAnchor" id="H27"><span class="h1">ALVEOLAR ECHINOCOCCOSIS (E. MULTILOCULARIS)</span><span class="headingEndMark"> — </span>The treatment of alveolar echinococcosis (AE) due to <em>E. multilocularis</em> is generally less effective than the treatment for cystic echinococcosis (CE) due to <em>E. granulosus</em>.</p><p>In general, the approach to treatment of AE consists of surgery (<a class="graphic graphic_table graphicRef121506" href="/z/d/graphic/121506.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef121504" href="/z/d/graphic/121504.html" rel="external">table 3</a>) [<a href="#rid98">98</a>]. Infected tissues should be removed as completely as possible, which requires complete excision of parasitic tissue and may also warrant radical resection of host tissue. The feasibility of radical resection depends on the site of the lesion, presence of metastases, patient comorbidities, and available surgical expertise.</p><p>The benefit of routine preoperative <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> administration is not known [<a href="#rid4">4</a>]. Postoperatively, albendazole (10 to 15 mg/kg per day in two divided doses; usual adult dose 400 mg twice daily) should be administered to reduce the likelihood of relapse, even in cases of apparent cure [<a href="#rid44">44</a>]. Alternative agents such as <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a>, <a class="drug drug_general" data-topicid="9805" href="/z/d/drug information/9805.html" rel="external">praziquantel</a>, <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>, and amphotericin are less effective than albendazole [<a href="#rid99">99,100</a>].</p><p>The optimal duration of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> is uncertain; in general, at least two years of therapy is advisable in conjunction with at least 10 years of follow-up monitoring for recurrence [<a href="#rid15">15</a>]. Local complications may develop that warrant intervention such as stenting, drainage of necrotic liver lesions, or endoscopic sclerosing of esophageal varices [<a href="#rid4">4</a>].</p><p>The role of palliative surgery is limited; in some cases, it may reduce the burden of infection and increase the benefit of adjunctive drug therapy [<a href="#rid101">101</a>].</p><p>Ex vivo liver resection and autotransplantation (ELRA) has shown promising outcomes in treating end-stage hepatic AE. One study found that long-term overall survival was more favorable among patients with AE who underwent ELRA than among patients who did not undergo surgery (five-year survival 82 versus 19 percent) [<a href="#rid102">102</a>]. </p><p>In cases that are not amenable to definitive surgery, <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> should be administered indefinitely to suppress progression of infection [<a href="#rid103">103</a>]. In such cases, albendazole is not curative but can improve quality of life and prolong survival. Survival rates at 15 years of 53 to 80 percent have been observed with palliative albendazole in the absence of surgery (versus 15 year mortality rate of 100 percent without treatment) [<a href="#rid104">104-110</a>]. Approximately half of patients respond with regression or lesion stabilization.</p><p>As a last resort, liver transplantation may be a consideration [<a href="#rid111">111,112</a>].</p><p class="headingAnchor" id="H3785987"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Management options for cystic echinococcosis (CE) include surgery, percutaneous management, drug therapy, and observation. In general, clinical approach depends on the World Health Organization (WHO) diagnostic classification (<a class="graphic graphic_table graphicRef71806" href="/z/d/graphic/71806.html" rel="external">table 1</a> and <a class="graphic graphic_diagnosticimage graphicRef87459" href="/z/d/graphic/87459.html" rel="external">image 1</a>). There are few randomized trials comparing different treatments, and the level of evidence supporting the use of one therapeutic modality over another is low. (See <a class="local">'Cystic echinococcosis (E. granulosus)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>WHO stage CE1 and CE3a cysts have a single compartment; such cysts &lt;5 cm may be treated with <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> alone. In settings where albendazole treatment with follow-up monitoring is not feasible, definitive management with percutaneous treatment via puncture, aspiration, injection, and reaspiration (PAIR) is an acceptable alternative approach. (See <a class="local">'Management approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>WHO stage CE1 and CE3a cysts that are &gt;5 cm may be treated with PAIR and adjunctive <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a>. In situations where albendazole treatment is not feasible, percutaneous treatment with PAIR (in the absence of adjunctive drug therapy) is an acceptable alternative approach. (See <a class="local">'Management approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>WHO stage CE2 and CE3b cysts have many compartments that require individual puncture; patients with such cysts commonly relapse after PAIR. Therefore, management of these cysts requires either modified catheterization technique (eg, non-PAIR percutaneous therapy) or surgery with adjunctive <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a>. (See <a class="local">'Management approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>WHO stage CE4 and CE5 cysts are inactive; antiparasitic treatment is not warranted in such cases. (See <a class="local">'Management approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Every effort should be made to avoid spillage of cyst contents, which can lead to secondary seeding of infection and/or anaphylaxis. For circumstances in which intact removal of the cyst is not feasible, a protoscolicidal agent should be injected into the cyst prior to removing the contents. (See <a class="local">'Techniques'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> for drug treatment of <em>Echinococcus granulosus</em> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>); in the absence of albendazole, <a class="drug drug_general" data-topicid="9594" href="/z/d/drug information/9594.html" rel="external">mebendazole</a> may be used as an alternative therapy. Albendazole is dosed 10 to 15 mg/kg per day in two divided doses; the usual dose for adults is 400 mg twice daily, taken with food. (See <a class="local">'Antiparasitic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal duration of definitive and adjunctive drug therapy is uncertain. Drug therapy for definitive treatment generally consists of one to three months; up to six months may be required. Drug therapy for adjunctive therapy consists of 4 to 30 days preoperatively and at least 4 weeks postoperatively. <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">Albendazole</a> should be administered continuously, without interruption. (See <a class="local">'Antiparasitic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CE can relapse years after treatment. The optimal approach to monitoring is uncertain and must be individualized. Follow-up for up to five years is warranted to evaluate for recurrence; three years may be sufficient if there is no recurrence on imaging studies at 12, 24, and 36 months. (See <a class="local">'Follow-up'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, the approach to treatment of alveolar echinococcosis consists of surgery (<a class="graphic graphic_table graphicRef121506" href="/z/d/graphic/121506.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef121504" href="/z/d/graphic/121504.html" rel="external">table 3</a>). Infected tissues should be removed as completely as possible, which requires complete excision of parasitic tissue and may also warrant radical resection of host tissue. In general, at least two years of adjunctive drug therapy is advisable in conjunction with at least 10 years of follow-up monitoring for recurrence. (See <a class="local">'Alveolar echinococcosis (E. multilocularis)'</a> above.)</p><p></p><p class="headingAnchor" id="H110953210"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Karin Leder and Dr. Peter Weller, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brunetti E, Kern P, Vuitton DA, Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1.</a></li><li><a class="nounderline abstract_t">Stojković M, Weber TF, Junghanss T. Clinical management of cystic echinococcosis: state of the art and perspectives. Curr Opin Infect Dis 2018; 31:383.</a></li><li><a class="nounderline abstract_t">Rinaldi F, Brunetti E, Neumayr A, et al. Cystic echinococcosis of the liver: A primer for hepatologists. World J Hepatol 2014; 6:293.</a></li><li><a class="nounderline abstract_t">Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ 1996; 74:231.</a></li><li><a class="nounderline abstract_t">Stojkovic M, Zwahlen M, Teggi A, et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis 2009; 3:e524.</a></li><li><a class="nounderline abstract_t">Aktan AO, Yalin R. Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst. Eur J Gastroenterol Hepatol 1996; 8:877.</a></li><li><a class="nounderline abstract_t">Erzurumlu K, Hökelek M, Gönlüsen L, et al. The effect of albendazole on the prevention of secondary hydatidosis. Hepatogastroenterology 2000; 47:247.</a></li><li><a class="nounderline abstract_t">Arif SH, Shams-Ul-Bari, Wani NA, et al. Albendazole as an adjuvant to the standard surgical management of hydatid cyst liver. Int J Surg 2008; 6:448.</a></li><li><a class="nounderline abstract_t">Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG, et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet 1993; 342:1269.</a></li><li><a class="nounderline abstract_t">Bildik N, Cevik A, Altintaş M, et al. Efficacy of preoperative albendazole use according to months in hydatid cyst of the liver. J Clin Gastroenterol 2007; 41:312.</a></li><li><a class="nounderline abstract_t">Manterola C, Mansilla JA, Fonseca F. Preoperative albendazole and scolices viability in patients with hepatic echinococcosis. World J Surg 2005; 29:750.</a></li><li><a class="nounderline abstract_t">Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd 1982; 67:5.</a></li><li><a class="nounderline abstract_t">El-On J. Benzimidazole treatment of cystic echinococcosis. Acta Trop 2003; 85:243.</a></li><li><a class="nounderline abstract_t">Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997; 64:79.</a></li><li><a class="nounderline abstract_t">Ammann RW, Eckert J. Cestodes. Echinococcus. Gastroenterol Clin North Am 1996; 25:655.</a></li><li><a class="nounderline abstract_t">Bezzi M, Teggi A, De Rosa F, et al. Abdominal hydatid disease: US findings during medical treatment. Radiology 1987; 162:91.</a></li><li><a class="nounderline abstract_t">Todorov T, Mechkov G, Vutova K, et al. Factors influencing the response to chemotherapy in human cystic echinococcosis. Bull World Health Organ 1992; 70:347.</a></li><li><a class="nounderline abstract_t">Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 1989; 67:503.</a></li><li><a class="nounderline abstract_t">Todorov T, Vutova K, Mechkov G, et al. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann Trop Med Parasitol 1992; 86:59.</a></li><li><a class="nounderline abstract_t">Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 1993; 37:1679.</a></li><li><a class="nounderline abstract_t">Todorov T, Vutova K, Mechkov G, et al. Evaluation of response to chemotherapy of human cystic echinococcosis. Br J Radiol 1990; 63:523.</a></li><li><a class="nounderline abstract_t">Horton RJ. Chemotherapy of Echinococcus infection in man with albendazole. Trans R Soc Trop Med Hyg 1989; 83:97.</a></li><li><a class="nounderline abstract_t">Vutova K, Mechkov G, Vachkov P, et al. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 1999; 93:357.</a></li><li><a class="nounderline abstract_t">Todorov T, Vutova K, Petkov D, et al. Albendazole treatment of human cystic echinococcosis. Trans R Soc Trop Med Hyg 1988; 82:453.</a></li><li><a class="nounderline abstract_t">Franchi C, Di Vico B, Teggi A. Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates. Clin Infect Dis 1999; 29:304.</a></li><li><a class="nounderline abstract_t">Keshmiri M, Baharvahdat H, Fattahi SH, et al. Albendazole versus placebo in treatment of echinococcosis. Trans R Soc Trop Med Hyg 2001; 95:190.</a></li><li><a class="nounderline abstract_t">Morris DL, Dykes PW, Marriner S, et al. Albendazole--objective evidence of response in human hydatid disease. JAMA 1985; 253:2053.</a></li><li><a class="nounderline abstract_t">Mohamed AE, Yasawy MI, Al Karawi MA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology 1998; 45:1690.</a></li><li><a class="nounderline abstract_t">Cobo F, Yarnoz C, Sesma B, et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop Med Int Health 1998; 3:462.</a></li><li><a class="nounderline abstract_t">Wen H, New RR, Craig PS. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 1993; 35:565.</a></li><li><a class="nounderline abstract_t">Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005; 9:69.</a></li><li><a class="nounderline abstract_t">McManus DP, Zhang W, Li J, Bartley PB. Echinococcosis. Lancet 2003; 362:1295.</a></li><li><a class="nounderline abstract_t">Taylor DH, Morris DL. Combination chemotherapy is more effective in postspillage prophylaxis for hydatid disease than either albendazole or praziquantel alone. Br J Surg 1989; 76:954.</a></li><li><a class="nounderline abstract_t">Yasawy MI, al Karawi MA, Mohamed AR. Combination of praziquantel and albendazole in the treatment of hydatid disease. Trop Med Parasitol 1993; 44:192.</a></li><li><a class="nounderline abstract_t">Yasawy MI, Alkarawi MA, Mohammed AR. Prospects in medical management of Echinococcus granulosus. Hepatogastroenterology 2001; 48:1467.</a></li><li><a class="nounderline abstract_t">Velasco-Tirado V, Alonso-Sardón M, Lopez-Bernus A, et al. Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis 2018; 18:306.</a></li><li><a class="nounderline abstract_t">Dervenis C, Delis S, Avgerinos C, et al. Changing concepts in the management of liver hydatid disease. J Gastrointest Surg 2005; 9:869.</a></li><li><a class="nounderline abstract_t">Rinaldi F, De Silvestri A, Tamarozzi F, et al. Medical treatment versus "Watch and Wait" in the clinical management of CE3b echinococcal cysts of the liver. BMC Infect Dis 2014; 14:492.</a></li><li><a class="nounderline abstract_t">Brunetti E, Garcia HH, Junghanss T, International CE Workshop in Lima, Peru, 2009. Cystic echinococcosis: chronic, complex, and still neglected. PLoS Negl Trop Dis 2011; 5:e1146.</a></li><li><a class="nounderline abstract_t">Junghanss T, da Silva AM, Horton J, et al. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 2008; 79:301.</a></li><li><a class="nounderline abstract_t">Brunetti E, Junghanss T. Update on cystic hydatid disease. Curr Opin Infect Dis 2009; 22:497.</a></li><li><a class="nounderline abstract_t">Khuroo MS, Dar MY, Yattoo GN, et al. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology 1993; 104:1452.</a></li><li><a class="nounderline abstract_t">Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 1997; 337:881.</a></li><li><a class="nounderline abstract_t">Brunetti E, White AC Jr. Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am 2012; 26:421.</a></li><li><a class="nounderline abstract_t">Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994; 88:295.</a></li><li><a class="nounderline abstract_t">Keshmiri M, Baharvahdat H, Fattahi SH, et al. A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis. Eur Respir J 1999; 14:503.</a></li><li><a class="nounderline abstract_t">Zlitni M, Ezzaouia K, Lebib H, et al. Hydatid cyst of bone: diagnosis and treatment. World J Surg 2001; 25:75.</a></li><li><a class="nounderline abstract_t">Singounas EG, Leventis AS, Sakas DE, et al. Successful treatment of intracerebral hydatid cysts with albendazole: case report and review of the literature. Neurosurgery 1992; 31:571.</a></li><li><a class="nounderline abstract_t">Todorov T, Vutova K, Petkov D, Balkanski G. Albendazole treatment of multiple cerebral hydatid cysts: case report. Trans R Soc Trop Med Hyg 1988; 82:150.</a></li><li><a class="nounderline abstract_t">Anadol D, Ozçelik U, Kiper N, Göçmen A. Treatment of hydatid disease. Paediatr Drugs 2001; 3:123.</a></li><li><a class="nounderline abstract_t">Safioleas MC, Misiakos EP, Kouvaraki M, et al. Hydatid disease of the liver: a continuing surgical problem. Arch Surg 2006; 141:1101.</a></li><li><a class="nounderline abstract_t">Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop 2009; 111:95.</a></li><li class="breakAll">World Health Organization (WHO) Informal Working Group of Echinococcosis. Puncture, Aspiration, Injection, Re-Aspiration. An option for the treatment of cystic echinococcosis, p. 1–40. Document WHO/CDS/CSR/SPH/2001.6. Geneva, Switzerland: WHO; 2001. pp. 1–40.</li><li><a class="nounderline abstract_t">Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis 2009; 13:125.</a></li><li><a class="nounderline abstract_t">Magistrelli P, Masetti R, Coppola R, et al. Surgical treatment of hydatid disease of the liver. A 20-year experience. Arch Surg 1991; 126:518.</a></li><li><a class="nounderline abstract_t">Behrns KE, van Heerden JA. Surgical management of hepatic hydatid disease. Mayo Clin Proc 1991; 66:1193.</a></li><li><a class="nounderline abstract_t">Di Matteo G, Bove A, Chiarini S, et al. Hepatic echinococcus disease: our experience over 22 years. Hepatogastroenterology 1996; 43:1562.</a></li><li><a class="nounderline abstract_t">Balik AA, Başoğlu M, Celebi F, et al. Surgical treatment of hydatid disease of the liver: review of 304 cases. Arch Surg 1999; 134:166.</a></li><li><a class="nounderline abstract_t">Safioleas M, Misiakos E, Manti C, et al. Diagnostic evaluation and surgical management of hydatid disease of the liver. World J Surg 1994; 18:859.</a></li><li><a class="nounderline abstract_t">Paksoy Y, Odev K, Sahin M, et al. Percutaneous treatment of liver hydatid cysts: comparison of direct injection of albendazole and hypertonic saline solution. AJR Am J Roentgenol 2005; 185:727.</a></li><li><a class="nounderline abstract_t">Dziri C, Haouet K, Fingerhut A, Zaouche A. Management of cystic echinococcosis complications and dissemination: where is the evidence? World J Surg 2009; 33:1266.</a></li><li><a class="nounderline abstract_t">Bickel A, Daud G, Urbach D, et al. Laparoscopic approach to hydatid liver cysts. Is it logical? Physical, experimental, and practical aspects. Surg Endosc 1998; 12:1073.</a></li><li><a class="nounderline abstract_t">Baskaran V, Patnaik PK. Feasibility and safety of laparoscopic management of hydatid disease of the liver. JSLS 2004; 8:359.</a></li><li><a class="nounderline abstract_t">Chowbey PK, Shah S, Khullar R, et al. Minimal access surgery for hydatid cyst disease: laparoscopic, thoracoscopic, and retroperitoneoscopic approach. J Laparoendosc Adv Surg Tech A 2003; 13:159.</a></li><li><a class="nounderline abstract_t">Ertem M, Karahasanoglu T, Yavuz N, Erguney S. Laparoscopically treated liver hydatid cysts. Arch Surg 2002; 137:1170.</a></li><li><a class="nounderline abstract_t">Seven R, Berber E, Mercan S, et al. Laparoscopic treatment of hepatic hydatid cysts. Surgery 2000; 128:36.</a></li><li><a class="nounderline abstract_t">Qian ZX. Thoracic hydatid cysts: a report of 842 cases treated over a thirty-year period. Ann Thorac Surg 1988; 46:342.</a></li><li><a class="nounderline abstract_t">Nasseri Moghaddam S, Abrishami A, Malekzadeh R. Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. Cochrane Database Syst Rev 2006; :CD003623.</a></li><li><a class="nounderline abstract_t">Neumayr A, Troia G, de Bernardis C, et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis-a systematic literature review. PLoS Negl Trop Dis 2011; 5:e1154.</a></li><li><a class="nounderline abstract_t">Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003; 37:1073.</a></li><li><a class="nounderline abstract_t">Salama H, Farid Abdel-Wahab M, Strickland GT. Diagnosis and treatment of hepatic hydatid cysts with the aid of echo-guided percutaneous cyst puncture. Clin Infect Dis 1995; 21:1372.</a></li><li><a class="nounderline abstract_t">Filice C, Brunetti E. Use of PAIR in human cystic echinococcosis. Acta Trop 1997; 64:95.</a></li><li><a class="nounderline abstract_t">Ustünsöz B, Akhan O, Kamiloğlu MA, et al. Percutaneous treatment of hydatid cysts of the liver: long-term results. AJR Am J Roentgenol 1999; 172:91.</a></li><li><a class="nounderline abstract_t">Men S, Hekimoğlu B, Yücesoy C, et al. Percutaneous treatment of hepatic hydatid cysts: an alternative to surgery. AJR Am J Roentgenol 1999; 172:83.</a></li><li><a class="nounderline abstract_t">Akhan O, Ozmen MN, Dinçer A, et al. Liver hydatid disease: long-term results of percutaneous treatment. Radiology 1996; 198:259.</a></li><li><a class="nounderline abstract_t">Yagci G, Ustunsoz B, Kaymakcioglu N, et al. Results of surgical, laparoscopic, and percutaneous treatment for hydatid disease of the liver: 10 years experience with 355 patients. World J Surg 2005; 29:1670.</a></li><li><a class="nounderline abstract_t">Filice C, Brunetti E. Echo-guided diagnosis and treatment of hepatic hydatid cysts. Clin Infect Dis 1997; 25:169.</a></li><li><a class="nounderline abstract_t">Akhan O, Salik AE, Ciftci T, et al. Comparison of Long-Term Results of Percutaneous Treatment Techniques for Hepatic Cystic Echinococcosis Types 2 and 3b. AJR Am J Roentgenol 2017; 208:878.</a></li><li><a class="nounderline abstract_t">Iscan M, Düren M. Endoscopic sphincterotomy in the management of postoperative complications of hepatic hydatid disease. Endoscopy 1991; 23:282.</a></li><li><a class="nounderline abstract_t">Spiliadis C, Georgopoulos S, Dailianas A, et al. The use of ERCP in the study of patients with hepatic echinococcosis before and after surgical intervention. Gastrointest Endosc 1996; 43:575.</a></li><li><a class="nounderline abstract_t">Dumas R, Le Gall P, Hastier P, et al. The role of endoscopic retrograde cholangiopancreatography in the management of hepatic hydatid disease. Endoscopy 1999; 31:242.</a></li><li><a class="nounderline abstract_t">Tarcin O. Rupture of hydatid cyst into the biliary tract. Gastrointest Endosc 2006; 63:325.</a></li><li><a class="nounderline abstract_t">Al Karawi MA, Mohamed AR, Yasawy I, Haleem A. Non-surgical endoscopic trans-papillary treatment of ruptured echinococcus liver cyst obstructing the biliary tree. Endoscopy 1987; 19:81.</a></li><li><a class="nounderline abstract_t">de Aretxabala X, Perez OL. The use of endoprostheses in biliary fistula of hydatid cyst. Gastrointest Endosc 1999; 49:797.</a></li><li><a class="nounderline abstract_t">Tekant Y, Bilge O, Acarli K, et al. Endoscopic sphincterotomy in the treatment of postoperative biliary fistulas of hepatic hydatid disease. Surg Endosc 1996; 10:909.</a></li><li><a class="nounderline abstract_t">Rodriguez AN, Sánchez del Río AL, Alguacil LV, et al. Effectiveness of endoscopic sphincterotomy in complicated hepatic hydatid disease. Gastrointest Endosc 1998; 48:593.</a></li><li><a class="nounderline abstract_t">Yilmaz U, Sakin B, Boyacioglu S, et al. Management of postoperative biliary strictures secondary to hepatic hydatid disease by endoscopic stenting. Hepatogastroenterology 1998; 45:65.</a></li><li><a class="nounderline abstract_t">Eickhoff A, Schilling D, Benz CA, Riemann JF. Endoscopic stenting for postoperative biliary strictures due to hepatic hydatid disease: effectiveness and long-term outcome. J Clin Gastroenterol 2003; 37:74.</a></li><li><a class="nounderline abstract_t">Hu B, Sun B, Cai Q, et al. Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures. Gastrointest Endosc 2017; 86:44.</a></li><li><a class="nounderline abstract_t">Golemanov B, Grigorov N, Mitova R, et al. Efficacy and safety of PAIR for cystic echinococcosis: experience on a large series of patients from Bulgaria. Am J Trop Med Hyg 2011; 84:48.</a></li><li><a class="nounderline abstract_t">Sciarrino E, Virdone R, Lo Iacono O, et al. Ultrasound changes in abdominal echinococcosis treated with albendazole. J Clin Ultrasound 1991; 19:143.</a></li><li><a class="nounderline abstract_t">Moro PL, Gilman RH, Verastegui M, et al. Human hydatidosis in the central Andes of Peru: evolution of the disease over 3 years. Clin Infect Dis 1999; 29:807.</a></li><li><a class="nounderline abstract_t">Galitza Z, Bazarsky E, Sneier R, et al. Repeated treatment of cystic echinococcosis in patients with a long-term immunological response after successful surgical cyst removal. Trans R Soc Trop Med Hyg 2006; 100:126.</a></li><li><a class="nounderline abstract_t">Ben Nouir N, Nuñez S, Gianinazzi C, et al. Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic echinococcosis. J Clin Microbiol 2008; 46:1631.</a></li><li><a class="nounderline abstract_t">Ben Nouir N, Gianinazzi C, Gorcii M, et al. Isolation and molecular characterization of recombinant Echinococcus granulosus P29 protein (recP29) and its assessment for the post-surgical serological follow-up of human cystic echinococcosis in young patients. Trans R Soc Trop Med Hyg 2009; 103:355.</a></li><li><a class="nounderline abstract_t">Zarzosa MP, Orduña Domingo A, Gutiérrez P, et al. Evaluation of six serological tests in diagnosis and postoperative control of pulmonary hydatid disease patients. Diagn Microbiol Infect Dis 1999; 35:255.</a></li><li><a class="nounderline abstract_t">Frider B, Larrieu E, Odriozola M. Long-term outcome of asymptomatic liver hydatidosis. J Hepatol 1999; 30:228.</a></li><li><a class="nounderline abstract_t">Vuitton DA, Azizi A, Richou C, et al. Current interventional strategy for the treatment of hepatic alveolar echinococcosis. Expert Rev Anti Infect Ther 2016; 14:1179.</a></li><li><a class="nounderline abstract_t">Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003; 47:467.</a></li><li><a class="nounderline abstract_t">Reuter S, Buck A, Grebe O, et al. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob Agents Chemother 2003; 47:3586.</a></li><li><a class="nounderline abstract_t">Kadry Z, Renner EC, Bachmann LM, et al. Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br J Surg 2005; 92:1110.</a></li><li><a class="nounderline abstract_t">Qiu Y, Huang B, Yang X, et al. Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis. Clin Infect Dis 2022; 75:1289.</a></li><li><a class="nounderline abstract_t">Torgerson PR, Schweiger A, Deplazes P, et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol 2008; 49:72.</a></li><li><a class="nounderline abstract_t">Ammann RW, Hirsbrunner R, Cotting J, et al. Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results). Am J Trop Med Hyg 1990; 43:506.</a></li><li><a class="nounderline abstract_t">Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992; 15:234.</a></li><li><a class="nounderline abstract_t">Wilson JF, Rausch RL, Wilson FR. Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos. Ann Surg 1995; 221:315.</a></li><li><a class="nounderline abstract_t">Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 1998; 29:994.</a></li><li><a class="nounderline abstract_t">Wilson JF, Rausch RL, McMahon BJ, et al. Albendazole therapy in alveolar hydatid disease: a report of favorable results in two patients after short-term therapy. Am J Trop Med Hyg 1987; 37:162.</a></li><li><a class="nounderline abstract_t">Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 1994; 19:735.</a></li><li><a class="nounderline abstract_t">Ishizu H, Uchino J, Sato N, et al. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Hepatology 1997; 25:528.</a></li><li><a class="nounderline abstract_t">Bresson-Hadni S, Koch S, Beurton I, et al. Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology 1999; 30:857.</a></li><li><a class="nounderline abstract_t">Bresson-Hadni S, Blagosklonov O, Knapp J, et al. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transpl 2011; 17:855.</a></li></ol></div><div id="topicVersionRevision">Topic 5671 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931502" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30124496" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical management of cystic echinococcosis: state of the art and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24868323" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cystic echinococcosis of the liver: A primer for hepatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8789923" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19787039" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment response of cystic echinococcosis to benzimidazoles: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8889454" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690616" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The effect of albendazole on the prevention of secondary hydatidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18819855" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Albendazole as an adjuvant to the standard surgical management of hydatid cyst liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7901585" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426473" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of preoperative albendazole use according to months in hydatid cyst of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15880282" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Preoperative albendazole and scolices viability in patients with hepatic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7041454" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chemotherapy for larval echinococcosis in animals and humans: report of a workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606103" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Benzimidazole treatment of cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9095290" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Albendazole in treatment of human cystic echinococcosis: 12 years of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8863045" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cestodes. Echinococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3538157" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Abdominal hydatid disease: US findings during medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1638663" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Factors influencing the response to chemotherapy in human cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2692867" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616396" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215283" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Therapy of human hydatid disease with mebendazole and albendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2202480" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of response to chemotherapy of human cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2603216" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chemotherapy of Echinococcus infection in man with albendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10656037" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3232185" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Albendazole treatment of human cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10476732" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11355559" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Albendazole versus placebo in treatment of echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883020" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Albendazole--objective evidence of response in human hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840130" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9657508" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8329280" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis and treatment of human hydatidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708321" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment options for hepatic cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14575976" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2804596" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combination chemotherapy is more effective in postspillage prophylaxis for hydatid disease than either albendazole or praziquantel alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256095" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Combination of praziquantel and albendazole in the treatment of hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677989" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prospects in medical management of Echinococcus granulosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976137" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Medical treatment of cystic echinococcosis: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985246" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Changing concepts in the management of liver hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25204575" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Medical treatment versus "Watch and Wait" in the clinical management of CE3b echinococcal cysts of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21814584" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cystic echinococcosis: chronic, complex, and still neglected.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784219" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical management of cystic echinococcosis: state of the art, problems, and perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633552" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Update on cystic hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8482455" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302302" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Percutaneous drainage compared with surgery for hepatic hydatid cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22632647" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cestode infestations: hydatid disease and cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944675" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10543267" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213159" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hydatid cyst of bone: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407437" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Successful treatment of intracerebral hydatid cysts with albendazole: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3176143" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Albendazole treatment of multiple cerebral hydatid cysts: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11269639" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116803" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hydatid disease of the liver: a continuing surgical problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375409" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19375409" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18938096" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Echinococcosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009069" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Surgical treatment of hydatid disease of the liver. A 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1749287" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Surgical management of hepatic hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8975966" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hepatic echinococcus disease: our experience over 22 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025457" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Surgical treatment of hydatid disease of the liver: review of 304 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7846909" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diagnostic evaluation and surgical management of hydatid disease of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16120926" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Percutaneous treatment of liver hydatid cysts: comparison of direct injection of albendazole and hypertonic saline solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350321" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Management of cystic echinococcosis complications and dissemination: where is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9685545" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Laparoscopic approach to hydatid liver cysts. Is it logical? Physical, experimental, and practical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15554281" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Feasibility and safety of laparoscopic management of hydatid disease of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12855097" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Minimal access surgery for hydatid cyst disease: laparoscopic, thoracoscopic, and retroperitoneoscopic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12361429" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Laparoscopically treated liver hydatid cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10876183" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Laparoscopic treatment of hepatic hydatid cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3046523" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Thoracic hydatid cysts: a report of 842 cases treated over a thirty-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625588" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21695106" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis-a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523772" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749617" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnosis and treatment of hepatic hydatid cysts with the aid of echo-guided percutaneous cyst puncture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9095291" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Use of PAIR in human cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9888746" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Percutaneous treatment of hydatid cysts of the liver: long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9888745" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Percutaneous treatment of hepatic hydatid cysts: an alternative to surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8539390" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Liver hydatid disease: long-term results of percutaneous treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16311852" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Results of surgical, laparoscopic, and percutaneous treatment for hydatid disease of the liver: 10 years experience with 355 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9243064" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Echo-guided diagnosis and treatment of hepatic hydatid cysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28199132" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of Long-Term Results of Percutaneous Treatment Techniques for Hepatic Cystic Echinococcosis Types 2 and 3b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1743130" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Endoscopic sphincterotomy in the management of postoperative complications of hepatic hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781936" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The use of ERCP in the study of patients with hepatic echinococcosis before and after surgical intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10344429" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The role of endoscopic retrograde cholangiopancreatography in the management of hepatic hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427946" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rupture of hydatid cyst into the biliary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3569154" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Non-surgical endoscopic trans-papillary treatment of ruptured echinococcus liver cyst obstructing the biliary tree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343233" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The use of endoprostheses in biliary fistula of hydatid cyst.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8703149" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Endoscopic sphincterotomy in the treatment of postoperative biliary fistulas of hepatic hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852449" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effectiveness of endoscopic sphincterotomy in complicated hepatic hydatid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496489" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Management of postoperative biliary strictures secondary to hepatic hydatid disease by endoscopic stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12811215" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Endoscopic stenting for postoperative biliary strictures due to hepatic hydatid disease: effectiveness and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283322" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Asia-Pacific consensus guidelines for endoscopic management of benign biliary strictures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21212200" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Efficacy and safety of PAIR for cystic echinococcosis: experience on a large series of patients from Bulgaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1849920" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ultrasound changes in abdominal echinococcosis treated with albendazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589894" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Human hydatidosis in the central Andes of Peru: evolution of the disease over 3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214196" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Repeated treatment of cystic echinococcosis in patients with a long-term immunological response after successful surgical cyst removal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367566" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19027129" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Isolation and molecular characterization of recombinant Echinococcus granulosus P29 protein (recP29) and its assessment for the post-surgical serological follow-up of human cystic echinococcosis in young patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10668582" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Evaluation of six serological tests in diagnosis and postoperative control of pulmonary hydatid disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10068100" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Long-term outcome of asymptomatic liver hydatidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27686694" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Current interventional strategy for the treatment of hepatic alveolar echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543645" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576122" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16044412" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35271705" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18485517" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240375" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520758" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717785" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875648" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3605498" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Albendazole therapy in alveolar hydatid disease: a report of favorable results in two patients after short-term therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8119701" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9049192" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498634" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21455928" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
